Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.52
NAS:SGYP's Cash-to-Debt is ranked lower than
68% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. NAS:SGYP: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SGYP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 0.52
0.13
No Debt
Equity-to-Asset -0.67
NAS:SGYP's Equity-to-Asset is ranked lower than
99% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SGYP: -0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SGYP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.67  Med: -0.02 Max: 0.63
Current: -0.67
-0.67
0.63
Debt-to-Equity -1.82
NAS:SGYP's Debt-to-Equity is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NAS:SGYP: -1.82 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SGYP' s Debt-to-Equity Range Over the Past 10 Years
Min: -67.77  Med: -2.28 Max: 6.31
Current: -1.82
-67.77
6.31
Debt-to-EBITDA -0.77
NAS:SGYP's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. NAS:SGYP: -0.77 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:SGYP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.99  Med: -1.02 Max: -0.16
Current: -0.77
-1.99
-0.16
Piotroski F-Score: 4
Altman Z-Score: -15.06
Beneish M-Score: 7.98
WACC vs ROIC
13.68%
921.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -435.78
NAS:SGYP's Operating Margin % is ranked lower than
92% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. NAS:SGYP: -435.78 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SGYP' s Operating Margin % Range Over the Past 10 Years
Min: -1321.04  Med: -1321.04 Max: -435.78
Current: -435.78
-1321.04
-435.78
Net Margin % -430.21
NAS:SGYP's Net Margin % is ranked lower than
91% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. NAS:SGYP: -430.21 )
Ranked among companies with meaningful Net Margin % only.
NAS:SGYP' s Net Margin % Range Over the Past 10 Years
Min: -1333.76  Med: -1333.76 Max: -430.21
Current: -430.21
-1333.76
-430.21
ROA % -117.27
NAS:SGYP's ROA % is ranked lower than
95% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NAS:SGYP: -117.27 )
Ranked among companies with meaningful ROA % only.
NAS:SGYP' s ROA % Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -69.97
Current: -117.27
-6858.53
-69.97
ROC (Joel Greenblatt) % -14401.28
NAS:SGYP's ROC (Joel Greenblatt) % is ranked lower than
98% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. NAS:SGYP: -14401.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SGYP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -219133.33  Med: -36739.14 Max: -14401.28
Current: -14401.28
-219133.33
-14401.28
3-Year EBITDA Growth Rate 0.50
NAS:SGYP's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NAS:SGYP: 0.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SGYP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.8 Max: 0.5
Current: 0.5
0
0.5
3-Year EPS without NRI Growth Rate 0.70
NAS:SGYP's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:SGYP: 0.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SGYP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -29 Max: 17.8
Current: 0.7
0
17.8
GuruFocus has detected 2 Warning Signs with Synergy Pharmaceuticals Inc NAS:SGYP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SGYP's 30-Y Financials

Financials (Next Earnings Date: 2018-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

SGYP Guru Trades in Q3 2017

Paul Tudor Jones 63,768 sh (New)
Robert Bruce 100,000 sh (unchged)
Louis Moore Bacon 225,000 sh (unchged)
John Paulson 24,062,368 sh (-0.11%)
» More
Q4 2017

SGYP Guru Trades in Q4 2017

Paul Tudor Jones 162,236 sh (+154.42%)
Louis Moore Bacon 225,000 sh (unchged)
Robert Bruce 100,000 sh (unchged)
John Paulson 4,000,000 sh (-83.38%)
» More
Q1 2018

SGYP Guru Trades in Q1 2018

Robert Bruce 100,000 sh (unchged)
John Paulson Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon 125,000 sh (-44.44%)
» More
Q2 2018

SGYP Guru Trades in Q2 2018

Robert Bruce 100,000 sh (unchged)
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2018-03-31 Sold Out 0.17%$1.75 - $2.64 $ 1.42-33%0
John Paulson 2017-12-31 Reduce -83.38%1.05%$1.84 - $3.46 $ 1.42-43%4,000,000
John Paulson 2017-11-30 Reduce -71.27%0.39%Premium Member Access $1.99 $ 1.42-29%4,400,000
John Paulson 2017-11-10 Reduce -36.36%0.45%Premium Member Access $2.82 $ 1.42-50%15,312,368
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:300452, KAR:GSKCH, XKRX:102460, XKRX:234080, XKRX:191420, TSXV:OGI, LSE:BMK, NAS:DEPO, BSP:OFSA3, SZSE:002817, TPE:3705, XKRX:008490, HKSE:02633, TSE:4577, NAS:PETQ, ASX:AC8, SZSE:300636, SZSE:300534, XKRX:214390, NAS:DRRX » details
Traded in other countries:S90.Germany,
Headquarter Location:USA
Synergy Pharmaceuticals Inc is a manufacturer of pharmaceutical products in the United States. It develops drugs for the treatment of gastrointestinal disorders such as constipation and irritable bowel syndrome.

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Top Ranked Articles about Synergy Pharmaceuticals Inc

FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.
Pomerantz Law Firm Announces the Filing of a Class Action against Synergy Pharmaceutical Inc. and Certain Officers – SGYP
Hagens Berman Alerts Synergy Pharmaceuticals Investors to the Securities Class Action Concerning Loan Disclosures and to the April 10, 2018 Lead Plaintiff Deadline
Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Synergy Pharmaceuticals Inc. - SGYP
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) To Contact Brower Piven Before The Lead Plaintiff Deadline
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
WeissLaw LLP Files Class Action Lawsuit Against Synergy Pharmaceuticals Inc.
SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm
John Paulson Reduces Synergy Pharmaceuticals After Heavy 3rd Quarter Health Care Selling Guru unloads another health care stock
John Paulson (Trades, Portfolio) axed another health care position on Nov. 30, he reported Tuesday, after backtracking on his huge exposure to the sector in the third quarter. Read more...

Ratios

vs
industry
vs
history
PS Ratio 9.66
SGYP's PS Ratio is ranked lower than
83% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGYP: 9.66 )
Ranked among companies with meaningful PS Ratio only.
SGYP' s PS Ratio Range Over the Past 10 Years
Min: 9.24  Med: 27.43 Max: 474
Current: 9.66
9.24
474
EV-to-EBIT -2.63
SGYP's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. SGYP: -2.63 )
Ranked among companies with meaningful EV-to-EBIT only.
SGYP' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.6  Med: -2.8 Max: -1.9
Current: -2.63
-4.6
-1.9
EV-to-EBITDA -2.63
SGYP's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. SGYP: -2.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGYP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.6  Med: -2.8 Max: -1.9
Current: -2.63
-4.6
-1.9
EV-to-Revenue 11.60
SGYP's EV-to-Revenue is ranked lower than
82% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. SGYP: 11.60 )
Ranked among companies with meaningful EV-to-Revenue only.
SGYP' s EV-to-Revenue Range Over the Past 10 Years
Min: 11.4  Med: 26.5 Max: 415.1
Current: 11.6
11.4
415.1
Current Ratio 2.83
SGYP's Current Ratio is ranked higher than
57% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SGYP: 2.83 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 3.09 Max: 11.88
Current: 2.83
0.04
11.88
Quick Ratio 2.31
SGYP's Quick Ratio is ranked higher than
58% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. SGYP: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.83 Max: 11.88
Current: 2.31
0.04
11.88
Days Inventory 473.34
SGYP's Days Inventory is ranked lower than
96% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. SGYP: 473.34 )
Ranked among companies with meaningful Days Inventory only.
SGYP' s Days Inventory Range Over the Past 10 Years
Min: 473.34  Med: 473.37 Max: 473.37
Current: 473.34
473.34
473.37
Days Sales Outstanding 88.13
SGYP's Days Sales Outstanding is ranked lower than
57% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. SGYP: 88.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGYP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 88.13  Med: 140.86 Max: 140.86
Current: 88.13
88.13
140.86
Days Payable 402.64
SGYP's Days Payable is ranked higher than
95% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. SGYP: 402.64 )
Ranked among companies with meaningful Days Payable only.
SGYP' s Days Payable Range Over the Past 10 Years
Min: 402.64  Med: 963.39 Max: 963.39
Current: 402.64
402.64
963.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.70
SGYP's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. SGYP: -36.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGYP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -243.5  Med: -21.2 Max: 17.7
Current: -36.7
-243.5
17.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.35
SGYP's Price-to-Median-PS-Value is ranked higher than
90% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. SGYP: 0.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGYP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.12 Max: 15.89
Current: 0.35
0.34
15.89
Earnings Yield (Greenblatt) % -37.56
SGYP's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. SGYP: -37.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGYP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -53.6  Med: -35.95 Max: -21.7
Current: -37.56
-53.6
-21.7

More Statistics

Revenue (TTM) (Mil) $35.25
EPS (TTM) $ -0.65
Beta1.90
Volatility40.18%
52-Week Range $1.28 - 3.19
Shares Outstanding (Mil)247.99

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 58 169 372 356
EBIT (Mil $) -116 -74 0 72
EBITDA (Mil $)
EPS ($) -0.50 -0.25 0.39 0.27
EPS without NRI ($) -0.50 -0.25 0.39 0.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}